We have advised Mallinckrodt on the spin-off of its Par Health generic pharmaceuticals and sterile injectables business, and Mallinckrodt’s evolution to become Keenova, focussed on branded therapeutics.

Our team was led by Stephen Ranalow (Partner, Corporate and M&A), Niamh O’Toole (Senior Associate, Corporate and M&A), Fintan Clancy (Partner, Tax), David Molloy (Partner, Debt Finance), Maeve Moran (Partner Corporate and M&A), Olivia Mullooly (Partner, Intellectual Property) and Colin Kavanagh (Partner, Life Sciences).

More information is available here: Introducing Keenova and Par Health